LLY Eli Lilly and Company Loading...

From DXCM earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
20:30
Jul 30 ◎
Jake Leach President and Chief Executive Officer, DexCom, Inc. DXCM Q2 FY26 call
The CONNECT trial showed that the largest relative improvement in A1C was within the cohort using only GLP-1 therapies, reinforcing the complementary relationship between CGM and incretin therapies. — As GLP-1 adoption grows, the market for CGM devices is likely to grow in tandem, especially if coverage expands alongside it, which is a positive read-through for the GLP-1 manufacturers.
LLY
MED

About LLY Analyst Coverage

Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jake Leach.